MAIA Biotechnology Inc. Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials

Reuters

06-24

<a href="https://laohu8.com/S/MAIA">MAIA Biotechnology Inc.</a> Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials

Maia Biotechnology Inc. has announced changes to its management team with the appointment of two prominent oncologists, Claudia Fulgenzi, MD, and David J. Pinato, MD, PhD, to its Scientific Advisory Board. Both experts will provide guidance on the design and protocols for Maia's upcoming clinical trial in hepatocellular carcinoma, focusing on the company's lead candidate ateganosine (THIO) combined with a checkpoint inhibitor. This development is part of Maia's ongoing efforts in targeted immunotherapies for cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624640390) on June 24, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545282521"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545282521\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545282521?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545282521","market":"nz","top_or_hot":-1,"title":"MAIA Biotechnology Inc. Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MAIA\">MAIA Biotechnology Inc.</a> Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maia Biotechnology Inc. has announced changes to its management team with the appointment of two prominent oncologists, Claudia Fulgenzi, MD, and David J. Pinato, MD, PhD, to its Scientific Advisory Board. Both experts will provide guidance on the design and protocols for Maia's upcoming clinical trial in hepatocellular carcinoma, focusing on the company's lead candidate ateganosine (THIO) combined with a checkpoint inhibitor. This development is part of Maia's ongoing efforts in targeted immunotherapies for cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624640390) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MAIA Biotechnology Inc. Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMAIA Biotechnology Inc. Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MAIA\">MAIA Biotechnology Inc.</a> Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Maia Biotechnology Inc. has announced changes to its management team with the appointment of two prominent oncologists, Claudia Fulgenzi, MD, and David J. Pinato, MD, PhD, to its Scientific Advisory Board. Both experts will provide guidance on the design and protocols for Maia's upcoming clinical trial in hepatocellular carcinoma, focusing on the company's lead candidate ateganosine (THIO) combined with a checkpoint inhibitor. This development is part of Maia's ongoing efforts in targeted immunotherapies for cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624640390) on June 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MAIA","symbol_name":"MAIA Biotechnology Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nNDL17JRfB:1","article_id":"2545282521","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545282521","pubTimestamp":1750767329,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MAIA Biotechnology Inc. Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials. Maia Biotechnology Inc. has announced changes to its management team with the appointment of two prominent oncologists, Claudia Fulgenzi, MD, and David J. Pinato, MD, PhD, to its Scientific Advisory Board. Both experts will provide guidance on the design and protocols for Maia's upcoming clinical trial in hepatocellular carcinoma, focusing on the company's lead candidate ateganosine  combined with a checkpoint inhibitor. This development is part of Maia's ongoing efforts in targeted immunotherapies for cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. publishe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MAIA":"MAIA Biotechnology Inc.","BK4139":"生物科技"},"translate_title":"MAIA Biotechnology Inc.任命领先的肿瘤学家Claudia Fulgenzi和David Pinato为即将进行的HCC临床试验的科学顾问委员会成员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MAIA":0.9},"content_text":"MAIA Biotechnology Inc. Appoints Leading Oncologists Claudia Fulgenzi and David Pinato to Scientific Advisory Board for Upcoming HCC Clinical Trials\n    \n\n        Maia Biotechnology Inc. has announced changes to its management team with the appointment of two prominent oncologists, Claudia Fulgenzi, MD, and David J. Pinato, MD, PhD, to its Scientific Advisory Board. Both experts will provide guidance on the design and protocols for Maia's upcoming clinical trial in hepatocellular carcinoma, focusing on the company's lead candidate ateganosine (THIO) combined with a checkpoint inhibitor. This development is part of Maia's ongoing efforts in targeted immunotherapies for cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250624640390) on June 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}